Pachymic acid protects against Crohn's disease-like intestinal barrier injury and colitis in miceby suppressingintestinal epithelial cell apoptosis via inhibiting PI3K/AKT signaling.
10.12122/j.issn.1673-4254.2023.06.08
- Author:
Rongrong SHAO
1
;
Zi YANG
2
;
Wenjing ZHANG
3
;
Nuo ZHANG
3
;
Yajing ZHAO
2
;
Xiaofeng ZHANG
4
;
Lugen ZUO
5
;
Sitang GE
5
Author Information
1. Cardiogram Room, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
2. Clinical Medical School, Bengbu 233000, China.
3. Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
4. Central Laboratory, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
5. Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
- Publication Type:Journal Article
- Keywords:
Crohn's disease;
apoptosis;
inflammatory bowel disease;
intestinal barrier;
pachymic acid
- MeSH:
Animals;
Mice;
Mice, Inbred C57BL;
Crohn Disease;
Phosphatidylinositol 3-Kinases;
Proto-Oncogene Proteins c-akt;
Interleukin-6;
Molecular Docking Simulation;
Tumor Necrosis Factor-alpha;
Colitis/chemically induced*;
Inflammation;
Apoptosis;
ErbB Receptors
- From:
Journal of Southern Medical University
2023;43(6):935-942
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of pachymic acid (PA) against TNBS-induced Crohn's disease (CD)-like colitis in mice and explore the possible mechanism.
METHODS:Twenty-four C57BL/6J mice were randomized equally into control group, TNBS-induced colitis model group and PA treatment group. PA treatment was administered via intraperitoneal injection at the daily dose of 5 mg/kg for 7 days, and the mice in the control and model groups were treated with saline. After the treatments, the mice were euthanized for examination of the disease activity index (DAI) of colitis, body weight changes, colon length, intestinal inflammation, intestinal barrier function and apoptosis of intestinal epithelial cells, and the expressions of TNF-α, IL-6 and IL-1β in the colonic mucosa were detected using ELISA. The possible treatment targets of PA in CD were predicted by network pharmacology. String platform and Cytoscape 3.7.2 software were used to construct the protein-protein interaction (PPI) network. David database was used to analyze the GO function and KEGG pathway; The phosphorylation of PI3K/AKT in the colonic mucosal was detected with Western blotting.
RESULTS:PA significantly alleviated colitis in TNBS-treated mice as shown by improvements in the DAI, body weight loss, colon length, and histological inflammation score and lowered levels of TNF-α, IL-6 and IL-1β. PA treatment also significantly improved FITC-dextran permeability, serum I-FABP level and colonic transepithelial electrical resistance, and inhibited apoptosis of the intestinal epithelial cells in TNBS-treated mice. A total of 248 intersection targets were identified between PA and CD, and the core targets included EGFR, HRAS, SRC, MMP9, STAT3, AKT1, CASP3, ALB, HSP90AA1 and HIF1A. GO and KEGG analysis showed that PA negatively regulated apoptosis in close relation with PI3K/AKT signaling. Molecular docking showed that PA had a strong binding ability with AKT1, ALB, EGFR, HSP90AA1, SRC and STAT3. In TNBS-treated mice, PA significantly decreased p-PI3K and p-AKT expressions in the colonic mucosa.
CONCLUSION:PA ameliorates TNBS-induced intestinal barrier injury in mice by antagonizing apoptosis of intestinal epithelial cells possibly by inhibiting PI3K/AKT signaling.
